Yüklüyor......
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886329/ https://ncbi.nlm.nih.gov/pubmed/20616894 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|